Skip to main content
OpenTrials
Completed

NCT Number: NCT05216835

Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Relapsed or Refractory Classical Hodgkin Lymphoma Disease Attributes Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence

Age range

16 year–101 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Research Site, Toronto, Ontario, Canada

Loading trial locations.

About this study

This is a Phase I/II, open-label multi-center study will have sabestomig administered via intravenous infusion on Cycle 1 Day 1 to adult/young adult patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL). This study will have 2 parts: Phase 1 (Part A) Dose Escalation and Phase 2 (Part B) Dose Expansion.

Patients will be treated with study intervention for a maximum of 35 cycles, or until disease progression, unacceptable toxicity, withdrawal of consent, or if other reasons to discontinue treatment occur.

The trial was intended to be Phase I/II trial (but the trial never moved forward to Phase 2). Hence, the study Phase was updated to Phase I.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 16 years of age at the time of obtaining informed consent
  • Eastern Cooperative Oncology Group performance status of 0 or 1 at screening
  • At least one positron emission tomography (PET)-avid measurable lesion according to Modified Lugano Criteria after the last line of therapy.
  • Confirmed histological diagnosis of active relapse/refractory cHL
  • Failed at least 2 prior lines of systemic therapy.
  • No previous treatment with anti-TIM-3.
  • Adequate organ and bone marrow function
  • Non-pregnant women and willingness of female patients to avoid pregnancy or male participants willing to avoid fathering children through highly effective methods of contraception
  • Minimum body weight ≥ 40 kg for all participants.

Exclusion criteria

  • Unresolved toxicities of ≥ Grade 2 from prior therapy
  • Any prior ≥ Grade 3 imAE while receiving prior checkpoint inhibitor immunotherapy
  • Patients with central nervous system (CNS) involvement or leptomeningeal disease.
  • History of allogeneic stem cell transplant or organ transplantation.
  • Any venous or arterial thromboembolic event within ≤ 6 months prior to the first dose of study intervention.
  • Active infection including Tuberculosis (TB), human immunodeficiency virus (HIV), hepatitis A, chronic or active hepatitis B, chronic or active hepatitis C, active COVID-19 infection
  • History of arrhythmia which is requires treatment, symptomatic or uncontrol led atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia
  • Uncontrolled intercurrent illness.
  • Active or prior documented pathologically confirmed autoimmune or inflammatory disorders.
  • Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
  • Other invasive malignancy within 2 years prior to screening
  • Congenital long QT syndrome or history of QT prolongation associated with other medications that cannot be changed or discontinued based on a cardiologist assessment
  • Current or prior use of immunosuppressive medication within 14 days prior to the first dose of study intervention
  • Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.

Treatment and study plan

Sabestomig (AZD7789)

Drug

Patients will receive sabestomig (PD-1/TIM-3 bispecific monoclonal antibody) via intravenous infusion.

Primary outcomes

  1. Part A (Dose Escalation): Number of Participants With Adverse Events (AEs)

    Time frame: From start of treatment [Cycle 1 Day 1 (C1D1) (each cycle was 28 days)] up to 90 days post last dose (approximately 2 years 5 months)

    The safety and tolerability of sabestomig in participants with r/r cHL were assessed.

  2. Part A (Dose Escalation): Number of Participants With Dose-limiting Toxicities (DLTs)

    Time frame: From first dose (C1D1) until 28 days for each participant [within 28 days DLT period]

    DLT was defined as any ≥Grade 3 AE as per NCI CTCAE version 5 unless unequivocally due to underlying malignancy or an extraneous cause.

    The following conditions were considered as DLTs:

    • Any death not clearly due to the underlying disease or extraneous causes
    • Grade 4 imAE or anemia
    • Any ≥Grade 3 non-infectious pneumonitis or colitis of any duration
    • Specific liver transaminase elevation as per protocol
    • Any Grade 3 imAE, including rash, pruritus, or diarrhea, that does not downgrade to Grade 2 or less within 7 days
    • Grade 3 nausea, vomiting, or diarrhea that does not resolve to Grade 2 or less within 3 days of getting maximal supportive care
    • ≥Grade 3 neutropenia, without fever or systemic infection, that does not improve by at least one grade within 7 days
    • Grade 4 thrombocytopenia for more than 7 days or ≥Grade 3 thrombocytopenia along with Grade ≥2 bleeding
    • Grade 4 Cytokine Release Syndrome (CRS) of any duration or Grade 3 CRS not improving to Grade ≤2 within 72 hours

  3. Part B (Dose Expansion): Cohort B1: Objective Response Rate (ORR)

    Time frame: Up to approximately 2 years 90 days

    The anti-tumor activity of sabestomig in participants with r/r cHL was planned to be assessed.

    ORR was defined as the percentage of participants with an objective response [Best Overall Response of a complete response (CR) or partial response (PR)] as per modified Lugano criteria (Lugano 2014), with the denominator defined as the number of participants in the response-evaluable analysis set.

    Disease response was planned to be assessed according to Blinded Independent Central Review using modified Lugano criteria (Lugano 2014).

  4. Part B (Dose Expansion): Cohort B2: Complete Response Rate (CRR)

    Time frame: Up to approximately 2 years 90 days

    The anti-tumor activity of sabestomig in participants with r/r cHL was planned to be assessed.

    The CRR was defined as the percentage of participants with a CR as per modified Lugano criteria (Lugano 2014), with the denominator defined as the number of participants in the response-evaluable analysis set.

    Disease response was planned to be assessed according to Blinded Independent Central Review using modified Lugano criteria (Lugano 2014).

  5. Part B (Dose Expansion): Number of Participants With AEs

    Time frame: Up to approximately 2 years 90 days

    The safety and tolerability of sabestomig in participants with r/r cHL was planned to be assessed.

Secondary outcomes

  1. Part A (Dose Escalation): Complete Response Rate (CRR)

    Time frame: From start of treatment [C1D1 (each cycle was 28 days)] until first documented disease progression, or last evaluable assessment in the absence of progression (up to 2 years 5 months)

    The anti-tumor activity of sabestomig in participants with r/r cHL was assessed.

    The CRR was defined as the percentage of participants with a CR as per modified Lugano criteria (Lugano 2014) as assessed by the Investigator, with the denominator defined as the number of participants in the response-evaluable analysis set.

    Disease response was assessed according to Investigator assessment using modified Lugano criteria (Lugano 2014).

  2. Part A (Dose Escalation): Objective Response Rate (ORR)

    Time frame: From start of treatment [C1D1 (each cycle was 28 days)] until progression, or last evaluable assessment in the absence of progression (up to 2 years 5 months)

    The anti-tumor activity of sabestomig in participants with r/r cHL was assessed.

    The ORR was defined as the percentage of participants with an objective response (Best Overall Response of CR or PR) as per modified Lugano criteria (Lugano 2014), as assessed by the Investigator, with the denominator defined as the number of participants in the response-evaluable analysis set.

    Disease response was assessed according to Investigator assessment using modified Lugano criteria (Lugano 2014).

  3. Part A (Dose Escalation): Duration of Response (DoR)

    Time frame: From first documented response until date of first documented disease progression or death from any cause, or data cut-off or end of study (whichever came first, assessed up to 2 years 5 months)

    The anti-tumor activity of sabestomig in participants with r/r cHL was assessed.

    The DoR was defined as the time from the date of first documented objective response (CR or PR), as assessed by Investigator, using the modified Lugano criteria (Lugano 2014), until the date of first documented disease progression or death (by any cause in the absence of disease progression).

    Disease response was assessed according to Investigator assessment using modified Lugano criteria (Lugano 2014).

  4. Part A (Dose Escalation): Duration of Complete Response (DoCR)

    Time frame: From first documented complete response until date of first documented disease progression or death from any cause, or data cut-off or end of study (whichever came first, assessed up to 2 years 5 months)

    The anti-tumor activity of sabestomig in participants with r/r cHL was assessed.

    The DoCR was defined as the time from first documented CR, as per modified Lugano criteria (Lugano 2014) as assessed by the Investigator, until the date of first documented relapse/progression or death due to any cause (in the absence of disease progression).

    Disease response was assessed according to Investigator assessment using modified Lugano criteria (Lugano 2014).

  5. Part A (Dose Escalation): Progression-free Survival (PFS)

    Time frame: From start of treatment [C1D1 (each cycle was 28 days)] until date of first documented disease progression or data cut-off or end of study (whichever came first, assessed up to 2 years 5 months)

    The anti-tumor activity of sabestomig in participants with r/r cHL was assessed.

    PFS was defined as the time from first dose until the earlier of the date of first documented disease progression, as per modified Lugano criteria (Lugano 2014) as assessed by the Investigator, or death (by any cause in the absence of disease progression or subsequent anticancer treatment).

    Disease response was assessed according to Investigator assessment using modified Lugano criteria (Lugano 2014).

  6. Part A (Dose Escalation): Overall Survival (OS)

    Time frame: From start of treatment [C1D1 (each cycle was 28 days)] until date of death due to any cause or data cut-off or end of study (whichever came first, assessed up to 2 years 5 months)

    The anti-tumor activity of sabestomig in participants with r/r cHL was assessed.

    The OS was defined as the time from the start of treatment until death due to any cause regardless of whether participant withdraws from treatment or receives another anti-lymphoma therapy.

  7. Part A (Dose Escalation): Number of Participants With Positive Anti-drug Antibodies (ADA) Against Sabestomig in Serum

    Time frame: On C1D1, C2D1, and until end of study [up to 2 years 5 months (each cycle was 28 days)]

    The presence of ADA for sabestomig in treated participants with r/r cHL was assessed.

  8. Part A (Dose Escalation): Maximum Observed Concentration (Cmax)

    Time frame: From C1D1 [before start of infusion (SOI) and at end of infusion (EOI)] to end of study [up to 2 years 5 months (each cycle was 28 days)]

    The Cmax of sabestomig in participants with r/r cHL was assessed.

  9. Part A (Dose Escalation): Area Under the Concentration-time Curve (AUC)

    Time frame: From C1D1 (before SOI and at EOI) to end of study [up to 2 years 5 months (each cycle was 28 days)]

    The AUC of sabestomig in participants with r/r cHL was assessed.

  10. Part A (Dose Escalation): Clearance (CL)

    Time frame: From C1D1 (before SOI and at EOI) to end of study [up to 2 years 5 months (each cycle was 28 days)]

    The CL of sabestomig in participants with r/r cHL was assessed.

  11. Part A (Dose Escalation): Terminal Elimination Half-life (t½λz)

    Time frame: From C1D1 (before SOI and at EOI) to end of study [up to 2 years 5 months (each cycle was 28 days)]

    The t½λz of sabestomig in participants with r/r cHL was assessed.

  12. Part B (Dose Expansion): Duration of Response (DoR)

    Time frame: Up to approximately 2 years 90 days

    The DoR of sabestomig in participants with r/r cHL was planned to be assessed.

  13. Part B (Dose Expansion): Duration of Complete Response (DoCR)

    Time frame: Up to approximately 2 years 90 days

    The DoCR of sabestomig in participants with r/r cHL was planned to be assessed.

  14. Part B (Dose Expansion): Progression-free Survival (PFS)

    Time frame: Up to approximately 2 years 90 days

    The anti-tumor activity of sabestomig in participants with r/r cHL was planned to be assessed.

  15. Part B (Dose Expansion): Overall Survival (OS)

    Time frame: Up to approximately 2 years 90 days

    The anti-tumor activity of sabestomig in participants with r/r cHL was planned to be assessed.

  16. Part B (Dose Expansion): Number of Participants With Positive ADA Against Sabestomig in Serum

    Time frame: Up to approximately 2 years 90 days

    The presence of ADA for sabestomig in treated participants with r/r cHL was planned to be assessed.

  17. Part B (Dose Expansion): Maximum Observed Concentration (Cmax)

    Time frame: Up to approximately 2 years 90 days

    The Cmax of sabestomig in participants with r/r cHL was planned to be assessed.

  18. Part B (Dose Expansion): Area Under the Concentration-time Curve (AUC)

    Time frame: Up to approximately 2 years 90 days

    The AUC of sabestomig in participants with r/r cHL was planned to be assessed.

  19. Part B (Dose Expansion): Terminal Elimination Half-life (t½λz)

    Time frame: Up to approximately 2 years 90 days

    The t½λz of sabestomig in participants with r/r cHL was planned to be assessed.

  20. Part B (Dose Expansion): Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Time frame: Up to approximately 2 years 90 days

    Proportion of participants reporting different levels of presence/magnitude/interference (as applicable) of diarrhea, rash, and fatigue over time based on PRO-CTCAE was planned to be evaluated.

    PRO-CTCAE was a PRO measurement system developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE Item Library included 124 items representing 78 symptomatic toxicities drawn from the CTCAE. PRO-CTCAE items were planned to evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. Each symptomatic AE was planned to be assessed by 1 to 3 attributes. Conditional branching logic was planned to be used with electronic data capture, thereby reducing respondent burden. The recall period was planned as the past 7 days and PRO-CTCAE responses were planned to score from 0 to 4 (or 0/1 for absent/present).

  21. Part B (Dose Expansion): Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (Peds-PRO-CTCAE)

    Time frame: Up to approximately 2 years 90 days

    Proportion of participants reporting different levels of presence/magnitude/interference (as applicable) of diarrhea, rash, and fatigue over time based on peds-PRO-CTCAE was planned to be evaluated.

    The pediatric module included 130 items representing 62 symptomatic toxicities and permitted self-reporting by children and adolescents aged 7 to 17 years. In this study, 17 symptomatic toxicities were planned for selection. Thus, the total number of questions that participants would have answered ranged from 17 (assuming that no branching questions were triggered, ie, the participant answered '0' to the initial question for each symptom) to 42 items (assuming that all possible branching questions were triggered for every symptom posed to the participant).

  22. Part B (Dose Expansion): Patient Global Impression of Treatment Tolerability (PGI-TT)

    Time frame: Up to approximately 2 years 90 days

    Proportion of participants reporting different levels of overall side-effect bother over time based on the PGI-TT was planned to be evaluated.

    For adult participants only, the PGI-TT item was included to assess how a participant perceived the overall burden of treatment-related side effects of cancer treatment over the past 7 days. Participants were planned to be asked to choose the response that best described the level of burden by the side effect of their cancer treatment over the past week. The planned response options were:"not at all", "a little bit", "somewhat", "quite a bit", and "very much".

  23. Part B (Dose Expansion): European Organization for Research and Treatment of Cancer (EORTC) Item List (IL)XX QL2 [2-item Global Health-related Quality of Life (HRQoL)]

    Time frame: Up to approximately 2 years 90 days

    Proportion of participants reporting different levels of quality of life/health over time based on the European Organization for Research and Treatment of Cancer Item List (EORTC) ILXX QL2 items was planned to be evaluated.

    EORTC QLQ-C30 was a 30-item self-administered questionnaire designed for all cancer types. Questions were grouped into 5 multi-item functional scales (physical, role, emotional, cognitive, and social), 3 multi-item symptom scales (fatigue, pain, and nausea/vomiting), 2-item global HRQoL (QL2) scale, 5 single items assessing additional symptoms commonly reported by participants with cancer (dyspnea, loss of appetite, insomnia, constipation, and diarrhea), and 1 item on the financial impact of the disease. Participants were planned to answer QLQ-C30 questions in reference to how they had been over the past week. Final scores were planned to transform to range from 0 to 100, where higher scores indicated better functioning, better HRQoL, or greater level of symptoms.

Other outcomes

  1. Part A (Dose Escalation): Number of Participants With Adverse Events of Special Interest (AESIs)

    Time frame: From start of treatment [C1D1 (each cycle was 28 days)] up to 90 days post last dose (approximately 2 years 5 months)

    The safety and tolerability of sabestomig in participants with r/r cHL were assessed.

    An AESI was an AE of scientific and medical interest specific to understanding of a study intervention and may have required close monitoring and rapid communication to AstraZeneca by the Investigator.

    The AESIs for sabestomig include events with a potential inflammatory or immune-mediated mechanism and which may require more frequent monitoring and/or interventions such as steroids, immunosuppressants and/or hormone replacement therapy.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Collaborators

  • Parexel

Registry information

Official study title

A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.

Important dates

Study start
2022
Primary completion
2024
Study completion
2025
First posted
Feb 1, 2022
Registry last updated
Oct 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.